Yang Shicong, Ye Ziyin, Wang Zhuo, Wang Liantang
Department of Pathology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Ann Transl Med. 2020 Sep;8(17):1082. doi: 10.21037/atm-20-4801.
Increased expression of high mobility group box 2 (HMGB2) has been reported to promote the progression of several malignancies and be related to poor outcome. However, few studies have explored the relationship between HMGB2 and osteosarcoma. In this study, we aimed to obtain a better understanding of HMGB2 and its function in osteosarcoma.
Utilizing osteosarcoma paraffin sections and osteosarcoma cell lines, we observed the clinico-pathological relationship of osteosarcoma with HMGB2 expression and investigated the functions of HMGB2 . The possible pathways and regulation networks in which HMGB2 is involved were further explored through analysis of miRNA, mRNA and lncRNA micro array data sets.
Strong expression of HMGB2 was found to be related with Enneking staging (P=0.002), tumor size (P=0.006), metastasis (P<0.001), and survival (P=0.011) in osteosarcoma. Multivariate analysis revealed that HMGB2 might have independent prognostic value in osteosarcoma (P=0.022). Kaplan-Meier curves and the log-rank test showed that survival time was significantly reduced in OS patients with strong HMGB2 expression (P=0.0056). experiments showed that HMGB2 overexpression promoted cell proliferation and enhanced the migration and invasion ability of osteosarcoma cells. Gene Ontology (GO) term analysis of osteosarcoma cell lines revealed HMGB2 to have various functions and to be mainly enriched in regulation of cell proliferation, cell death, and DNA binding. A competing endogenous RNA (ceRNA) network of miR-139-5p and six candidate lncRNAs was also suggested as targeting HMGB2 in osteosarcoma.
Our findings suggest that HMGB2 might have various functions in promoting the progression of osteosarcoma and may serve as a new target for osteosarcoma research.
据报道,高迁移率族蛋白盒2(HMGB2)表达增加可促进多种恶性肿瘤的进展,并与不良预后相关。然而,很少有研究探讨HMGB2与骨肉瘤之间的关系。在本研究中,我们旨在更好地了解HMGB2及其在骨肉瘤中的功能。
利用骨肉瘤石蜡切片和骨肉瘤细胞系,我们观察了骨肉瘤与HMGB2表达的临床病理关系,并研究了HMGB2的功能。通过对miRNA、mRNA和lncRNA微阵列数据集的分析,进一步探索了HMGB2参与的可能途径和调控网络。
发现HMGB2的强表达与骨肉瘤的Enneking分期(P=0.002)、肿瘤大小(P=0.006)、转移(P<0.001)和生存率(P=0.011)相关。多变量分析显示,HMGB2可能在骨肉瘤中具有独立的预后价值(P=0.022)。Kaplan-Meier曲线和对数秩检验表明,HMGB2表达强的骨肉瘤患者生存时间显著缩短(P=0.0056)。实验表明,HMGB2过表达促进细胞增殖,并增强骨肉瘤细胞的迁移和侵袭能力。骨肉瘤细胞系的基因本体(GO)术语分析显示,HMGB2具有多种功能,主要富集于细胞增殖调控、细胞死亡调控和DNA结合。还提出了一个miR-139-5p和六个候选lncRNA的竞争性内源RNA(ceRNA)网络作为骨肉瘤中靶向HMGB2的网络。
我们的研究结果表明,HMGB2可能在促进骨肉瘤进展中具有多种功能,并可能成为骨肉瘤研究的新靶点。